Characteristics
PP(−) (n = 143) PP(+) (n = 89)
P
Age group, n (%) Age group, n (%) Age group, n (%) Age group, n (%)
65–74 87 (60.8) 52 (58.4) 0.82
≥ 75 56 (39.2) 37 (41.6)
Sex, n (%) Sex, n (%) Sex, n (%) Sex, n (%)
Female 104 (72.7) 68 (76.4) 0.64
Male 39 (27.3) 21 (23.6)
Smoking status, n (%) Smoking status, n (%) Smoking status, n (%) Smoking status, n (%)
Brinkman index <400 108 (75.5) 60 (67.4) 0.23
Brinkman index ≥400 35 (24.5) 29 (32.6)
ECOG-PS, n (%) ECOG-PS, n (%) ECOG-PS, n (%) ECOG-PS, n (%)
0/1 116 (81.1) 63 (70.8) 0.097
≥ 2 27 (18.9) 26 (29.2)
BMI, n (%) BMI, n (%) BMI, n (%) BMI, n (%)
< 18.5 36 (25.2) 18 (20.2) 0.13
≥ 18.5 94 (65.7) 68 (76.4)
Histological subtypes, n (%) Histological subtypes, n (%) Histological subtypes, n (%) Histological subtypes, n (%)
Adenocarcinoma 133 (93.0) 83 (93.3) 1.00
Other 10 (7.0) a 6 (6.7) b
Staging, n (%) Staging, n (%) Staging, n (%) Staging, n (%)
III 7 (4.9) 1 (1.1) 0.33
IVA 31 (21.7) 15 (16.9)
IVB 71 (49.7) 50 (26.2)
Recurrence 34 (23.8) 23 (25.8)
Number of organs involved in metastasis, n (%) Number of organs involved in metastasis, n (%) Number of organs involved in metastasis, n (%) Number of organs involved in metastasis, n (%)
0/1 79 (55.2) 40 (44.9) 0.16
≥ 2 64 (44.8) 49 (55.1)
Presence of brain metastasis, n (%) Presence of brain metastasis, n (%) Presence of brain metastasis, n (%) Presence of brain metastasis, n (%)
Yes 40 (28.0) 25 (28.1) 1.00
Presence of bone metastasis, n (%) Presence of bone metastasis, n (%) Presence of bone metastasis, n (%) Presence of bone metastasis, n (%)
Yes 47 (32.9) 38 (42.7) 0.17
Presence of liver metastasis, n (%) Presence of liver metastasis, n (%) Presence of liver metastasis, n (%) Presence of liver metastasis, n (%)
Yes 24 (16.8) 17 (19.1) 0.79
EGFR mutation status, n (%) EGFR mutation status, n (%) EGFR mutation status, n (%) EGFR mutation status, n (%)
Exon 19 del 56 (39.2) 36 (40.4) 0.88
Exon 21 L858R 74 (51.7) 46 (51.7)
Other 11 (8.4) c 7 (7.9) d
Initially chosen EGFR-TKIs, n (%) Initially chosen EGFR-TKIs, n (%) Initially chosen EGFR-TKIs, n (%) Initially chosen EGFR-TKIs, n (%)
Gefitinib 92 (64.3) 64 (71.9) 0.16
Erlotinib 22 (15.4) 16 (18.0)
Afatinib 9 (6.3) 1 (1.1)
Osimertinib 20 (14.0) 8 (9.0)
Combination with other antitumor agents, n (%) Combination with other antitumor agents, n (%) Combination with other antitumor agents, n (%) Combination with other antitumor agents, n (%)
Yes 24 (16.8) 7 (78.7) 0.081
Lines of EGFR-TKIs use Lines of EGFR-TKIs use Lines of EGFR-TKIs use Lines of EGFR-TKIs use
First 117 (81.8) 71 (79.8) 0.83
Second or later 26 (18.2) 18 (20.2)
Osimertinib use in clinical course, i (%) Osimertinib use in clinical course, i (%) Osimertinib use in clinical course, i (%) Osimertinib use in clinical course, i (%)
Yes 48 (33.6) 18 (20.2) 0.041
CCI, n (%) CCI, n (%) CCI, n (%) CCI, n (%)
≤ 6 99 (69.2) 44 (49.4) 0.004
≥ 7 54 (37.8) 45 (50.6)
GRIm-Score, n (%) GRIm-Score, n (%) GRIm-Score, n (%) GRIm-Score, n (%)
0/1 121 (84.6) 68 (76.4) 0.25
2/3 20 (14.0) 20 (22.5)